September 18, 2024
8PM ET
The last two years have seen rapid advancement in therapy options for EoE, moving beyond dietary elimination, off-label use of proton pump inhibitors and swallowed topical steroids. In May of 2022, dupilumab became the first FDA approved medication for EoE in patients 12 years and older, and January 2024 brought approval for ages 1-11. Next came the first and only oral medication approved for EoE – budesonide oral suspension EOHILIA. These changes have resulted in questions around best approaches and practices in treating EoE patients.
Navigating the Rapidly Changing Landscape of EoE Treatment will deliver a particular focus on new medication options for pediatric patients with EoE as well as challenges faced by clinicians and patients.
Register today!
